Theme: Media influence on hemostasis.

 
 
1. Specify the possible mechanisms of action of substances that reduce platelet
aggregation: 
1.A decrease in the synthesis of thromboxane in platelets. 
2. Tromboksanov blockade of platelet receptors 
3. Blockade of prostacycline platelet receptors. 
4.Blockade of platelet glycoprotein receptors. 
5. Blockade of purine receptors of platelets. 
6. Blockade of serotonin receptors on platelets. 
2. For acetylsalicylic acid is characterized by: 
1. Inhibits cyclooxygenase and disrupts the formation of thromboxane. 
2. Tromboksanov blocks receptors of platelets. 
3. Prostacycline stimulates receptors of platelets. 
4.Blocks glycoprotein receptors of platelets. 
5.It has an antiplatelet effect in low doses. 
3. Indications for the appointment of Acetylsalicylic acid: 
1.Hemophilia A. 
2.Antidote for overdose. heparin's. 
3.Prevention of repeated strokes and heart attacks. 
4. The drug recombinant tissue plasminogen activator: 
1.Heparin 
2.Streptokinase. 
3.Alteplase. 
4.Anistreplase 
5. Preparations from the culture of β-hemolytic Streptococcus: 
1.Heparin 
2.Streptokinase. 
3.Alteplase. 
4.Anistreplase 
5.Integrilin. 
6. The mechanism of antiplatelet action abziksimaba: 
1.Tromboksanov blocks receptors of platelets. 
2.Inhibits cyclooxygenase and disrupts the formation of thromboxane. 
3.Prostacycline stimulates receptors of platelets. 
4. Blocking of purine receptors of platelets and inhibits the action of ADP. 
5. Blocks glycoprotein receptors of platelets and prevents fibrinogen binding
to them. 
7. Dipyridamole is characterized by: 
1.Blocks glycoprotein receptors of platelets. 
2.Inhibits cyclooxygenase and disrupts the formation of thromboxane. 
3.Inhibits platelet phosphodiesterase and increases the concentration of
camp. 
4. Causes a corona-widening effect. 
8. Antiplatelet agents prescribed: 
1.Only to dissolve fresh blood clots. 
2. Only to prevent blood clots. 
9. Epoprostenol is characterized by: 
1.Inhibits platelet aggregation. 
2.Stimulates prostacycline receptors. 
3.Blocks prostacycline receptors. 
4.Constricts the vessels. 
5. Dilates the vessels. 
6. There is a very short-lived. 
7.It works for a long time. 
10. For heparin characteristic: 
1. Effective when taken orally. 
2.Effective with parenteral administration. 
3. Disrupts blood clotting only in vivo. 
4. It disrupts blood clotting in vivo and in vitro. 
5. After injection into the vein, the action occurs immediately after injection
and lasts 2-6 hours. 
6. Antagonist heparin – Protamine sulfate. 
11. Preparation of streptokinase and acylated plasminogen: 
1.Heparin. 
2.Alteplase. 
3.Anistreplase 
4.Abciximab. 
5.Eptifibatide. 
12. Irreversible non-selective inhibition of cyclooxygenase causes: 
1.Abciximab. 
2.Clopidogrel 
3.Indobufen 
4.Acetylsalicylic acid 
13. Drug ativanlorazepam belongs to the pharmacological group: 
1.Antifibrinolytic agent. 
2.Preparations of blood clotting factors. 
3.Anticoagulants indirect action, act through 12-30 no. 
4.Anticoagulants of indirect action, act 24-48 hours. 
14. Mechanism of antiplatelet action of clopidogrel and ticlopidine: 
1.Tromboksanov blocks receptors of platelets. 
2.Inhibits cyclooxygenase and disrupts the formation of thromboxane. 
3.Prostacycline stimulates receptors of platelets. 
4.Blocking of purine receptors of platelets and inhibits the action of ADP. 
5. Blocks glycoprotein receptors of platelets. 
15.Mechanism of anticoagulant action of nadroparin: 
1.Depressing (in complex with antithrombin III) perepodpisana to thrombin and
inhibits thrombin. 
2. Inhibits the recovery of vitamin K in the active form, preventing the synthesis of
coagulation factors in the liver. 
3. Inhibits (regardless of antithrombin III) the transition of prothrombin to
thrombin and inhibits thrombin. 
4. Inhibits (in combination with antithrombin III) the transition of
prothrombin to thrombin and does not inhibit thrombin. 
16. Low molecular weight heparins are characterized by: 
1.Increases the depressing effect of antithrombin III on the transition of
prothrombin to thrombin. 
2.Against the background of the drugs there is no inhibition of thrombin
activity. 
3.Against the background of the drug activity of thrombin inhibited to a greater
extent than against the background of heparin. 
4.Have a pronounced antiplatelet activity. 
17. For the typical lepirudin: 
1. It is a direct-acting anticoagulant. 
2. It violates the synthesis of prothrombin in the liver. 
3. Inhibits thrombin, the coupling with antithrombin III. 
4. It has a direct inhibitory effect on thrombin, independent of antithrombin
III. 
18. Inhibitor of ADP interaction with platelet membrane receptors: 
1.Eptifibatide. 
2.Clopidogrel 
3.Heparin. 
4.Alteplase. 
5.Anistreplase 
19. Preparation of recombinant coagulation factor VIIa: 
1.Alteplase. 
2.NovoSeven. 
3.Anistreplase 
4.Abciximab. 
5.Eptifibatide. 
20. Reversible indiscriminate inhibition of cyclooxygenase and inhibition of
thromboxane A2-synthetase causes: 
1.NovoSeven. 
2.Abciximab. 
3.Clopidogrel 
4.Indobufen 
5.Acetylsalicylic acid 
21. The drug tranexamic acid belongs to the pharmacological group: 
1.Antifibrinolytic agents. 
2.Preparations of blood clotting factors. 
3.Anticoagulants indirect action, act through 12-30 no. 
4.Anticoagulants of indirect action, act 24-48 hours. 
5.Phosphodiesterase inhibitors. 
22. The mechanism of the anticoagulant action of heparin: 
1. Inhibits the synthesis of prothrombin in the liver. 
2. Binds calcium ions, disrupting the transition of prothrombin to thrombin. 
3. Increases the depressing effect of antithrombin III on the transition of
prothrombin to thrombin and thrombin. 
23. Means, increasing blood clotting: 
1. Vitamin K.  
2. Acid aminocapronova. 
3. Thrombin. 
4. Fraxiparin. 
5. Fibrinogen. 
24.Mechanism of anticoagulant action of indirect anticoagulants: 
1. Inhibit the synthesis of prothrombin and proconvertin in the liver, being an
antagonist of vitamin K1. 
2. Disrupts the transition of prothrombin to thrombin. 
3. Inhibits thrombin. 
25. For anticoagulants indirect action is characterized by: 
1. Introduced inside. 
2. Administered parenterally. 
3. The action develops immediately and lasts 2-4 hours. 
4. The action develops slowly and lasts 2-4 days. 
5. Effective only in vivo. 
6. Effective in vivo and in vitro. 
7. Cumulate. 
8. Used to prevent thrombosis. 
9. The antagonist of vitamin K1. 
26. Phosphodiesterase inhibitor: 
1.Eptifibatide. 
2.Clopidogrel 
3.Dipyridamole 
4.Alteplase. 
5.Anistreplase 
27. The drug recombinant tissue plasminogen activator: 
1.Alteplase. 
2.NovoSeven. 
3.Anistreplase 
4.Abciximab. 
5.Eptifibatide. 
28. Non-competitive blockade of the receptor glycoprotein llb/llla causes: 
1.NovoSeven. 
2.Abciximab 
3.Clopidogrel 
4.Indobufen 
5.Acetylsalicylic acid 
29. The drug pentoxifylline belongs to the pharmacological group: 
1.Antifibrinolytic agent. 
2.Preparations of blood clotting factors. 
3.Anticoagulants indirect action, act through 12-30 no. 
4.Anticoagulants of indirect action, act 24-48 hours. 
5.Inhibitors of phosphodiesterase 
30. Indications for the appointment of Protamine sulfate: 
1.Hemophilia A 
2.Antidote for overdose of heparin 
3.Prevention of repeated strokes and heart attacks 
31.Streptokinase is characterized by: 
1. Causes fibrinolytic effect, interacting with the profibrinolizin. 
2. Stimulates the transition of profibrinolysin into fibrinolysin only in the blood
clot. 
3. Stimulates the transition of profibrinolysin in fibrinolysin in the blood clot
and plasma. 
32. For tissue activator profibrinolizina characteristic: 
1. Stimulates the transition of profibrinolysin into fibrinolysin mainly in the
blood clot. 
2. To a much lesser extent than streptokinase activates the fibrinolytic
system. 
3. Stimulates the transition of profibrinolysin in fibrinolysin in the blood clot and
plasma. 
33.Direct-acting anticoagulant: 
1.Eptifibatide. 
2.Clopidogrel 
3.Heparin 
4Alteplase. 
5.Anistreplase 
34.Inhibition (in combination with antithrombin III) the transition of
prothrombin to thrombin and thrombin inhibition causes: 
1.NovoSeven. 
2.Abciximab. 
3.Clopidogrel 
4.Indobufen 
5.Heparin 
35. The drug ticlopidine belongs to the pharmacological group: 
1.Antifibrinolytic agent. 
2.Preparations of blood clotting factors. 
3.Anticoagulants indirect action, act through 12-30 no. 
4.Anticoagulants of indirect action, act 24-48 hours. 
5.Inhibitor of ADP interaction with platelet membrane receptors. 
36. Fibrinolytic agents are used: 
1. Only to prevent blood clots. 
2. Only to dissolve fresh blood clots. 
37. Mechanisms of antifibrinolytic action of aminocaproic acid: 
1. Inhibits the transition of profibrinolysin into fibrinolysin, inhibiting the
activators of this process. 
2. It has a direct depressing effect on fibrinolysin. 
3. Acting directly on the fibrin, stabilizing it. 
38.Cox-1 inhibitor: 
1.Eptifibatide. 
2.Clopidogrel 
3.Indobufen 
4.Alteplase. 
5.Anistreplase 
39. Inhibits the recovery of vitamin K in the active form,preventing the
synthesis of coagulation factors in the liver: 
1.NovoSeven. 
2.Acenocoumarol 
3.Clopidogrel 
4.Indobufen 
5.Heparin 
40. The drug, tirofiban belongs to the pharmacological group: 
1.Antifibrinolytic agent. 
2.Preparations of blood clotting factors. 
3.Non-peptide glycoprotein blocker  
4.Anticoagulants of indirect action, act 24-48 hours. 
5.Inhibitor of ADP interaction with platelet membrane receptors. 
41. Indications for the appointment of streptokinase: 
1.Hemophilia A. 
2.Coronary thrombosis of the heart. 
42. Indications for use of antifibrinolytic agents: 
1. Tendency to thrombosis. 
2. Bleeding associated with increased fibrinolysis. 
3. Streptokinase overdose. 
43. Reduce platelet aggregation. 
1.Abciximab. 
2. Alteplase. 
3.Neodikumarin. 
4.Clopidogrel. 
5.Etamzilat 
44.Anticoagulant indirect action, acts through 12-30 no.: 
1.Eptifibatide. 
2.Clopidogrel 
3.Etibiscumacetate 
4.Alteplase. 
5.Anistreplase 
45.Inhibits (independent of antithrombin III) the transition of prothrombin to
thrombin and inhibits thrombin: 
1.NovoSeven. 
2.Acenocoumarol 
3.Lepirudin 
4.Clopidogrel 
5.Indobufen 
6.Heparin 
46. It promotes fibrinolysis and acts only in the blood clot. 
1. Streptokinase. 
2. Tranexamic acid. 
3. Alteplase. 
4. Urokinase. 
5. Heparin. 
47. Prevent fibrinolysis and are used to stop bleeding. 
1. Streptokinase. 
2. Tranexamic acid. 
3. Aminocaproic acid. 
4. Alteplase. 
48.Anticoagulant indirect action, acts after 24-48 hours: 
1.Eptifibatide. 
2.Acenocoumarol 
3.Etibiscumacetate 
4.Alteplase. 
5.Anistreplase 
49. The drug tranexamic acid belongs to the pharmacological group: 
1.Antifibrinolytic agent. 
2.Fractionated direct-acting anticoagulant. 
3.Non-peptide glycoprotein blocker  
4.Anticoagulants of indirect action, act 24-48 hours. 
5.Inhibitor of ADP interaction with platelet membrane receptors. 
50. Indications for the appointment of sulodexide: 
1.Hemophilia A. 
2.Coronary thrombosis of the heart. 
3.Prevention of repeated strokes and heart attacks. 
4.Vascular disease with risk of thrombosis. 
51. Reduces platelet aggregation due to inhibition of thromboxane
biosynthesis. With increasing dose or frequency of administration of
antiplatelet action decreases: 
1. Abciximab. 
2. Clopidogrel. 
3. Dipyridamole. 
4. Acetylsalicylic acid. 
52. Reduces blood clotting. It is injected under the skin and intravenously.
When administered intravenously, the action develops immediately and lasts
4-6 hours. 
1. Nadroparin 
2. Acenocumarol. 
3. Heparin. 
4. Enoxaparin. 
53. The drug vitamin K1: 
1.Eptifibatide. 
2.Fitomenadion 
3.Etibiscumacetate 
4.Alteplase. 
5.Vicasolum 
54. Reduces blood clotting. It has a slow development of the effect. It is used
inside. The effect reaches a maximum after 24-48 hours. Overdose used
fitomenadion: 
1. Nadroparin. 
2. Acenocumarol. 
3. Heparin. 
4. Enoxaparin. 
55.Fibrinolytic agent. Administered intravenously drip. Acts as a blood clot
and plasma. Fibrinolytic effect has only in combination with plasminogen. It
is used both for the prevention of thromboembolic complications and for
dissolving fresh blood clots. As side effects causes bleeding, can cause
anaphylactic shock: 
1. Tranexamic acid. 
2. Alteplase. 
3. Streptokinase. 
4. Urokinase. 
56. Antifibrinolytic agent inactivates the activation of plasminogen. It is used
intravenously and inside: 
1. Tranexamic acid. 
2. Alteplase. 
3. Aprotinin.  
4. Urokinase. 
57.Vitamin K3 preparation: 
1.Eptifibatide. 
2.Fitomenadion 
3.Etibiscumacetate 
4.Alteplase. 
5.Vicasolum 
58. The preparation of the group angioprotectors has gemostaticski action: 
1.Etamzilat 
2.NovoSeven. 
3.Sulodexide 
4.Cryoprecipitate 
5.Eptifibatide. 
59.Antifibrinolytic agent: 
1.NovoSeven. 
2.Aminocaproic acid 
3.Lepirudin 
4.Clopidogrel 
5.Indobufen 
60.Abciximab causes: 
1. Irreversible non-selective inhibition of cyclooxygenase 
2. Reversible indiscriminate inhibition of cyclooxygenase and inhibition of
thromboxane A2-synthetase 
3. .Blockade of purinergic (P) receptors  
4. Non-competitive blockade of the receptor glycoprotein llb/llla  
5. Inhibition of phosphodiesterase 
61. Testimony to the appointment of infukol: 
1.Prevention and treatment of shock of different Genesis. 
2.Prevention and treatment of hypovolemia. 
3.Prevention of repeated strokes and heart attacks. 
4.Vascular disease with risk of thrombosis. 
62. Preparations containing proteolytic enzymes: 
1.Pepsin  
2.Acidin-pepsin 
3.Natural gastric juice 
4.Nucleic acid 
5.Peptidyl (extract of the gastric mucosa of pigs) 
6.Abomin 
63. Have proteolytic activity (cleave proteins, nucleic acids). Applied to liquefy
viscous secretions and exudates and remove them with sputum from the VDP
(bronchitis, lung atelectasis, tuberculosis), administered in the form of
inhalations, intrapleural, with electrophoresis, intramuscularly; local - in the
treatment of burns, purulent wounds, bedsores: 
1.Trypsin 
2.Chymotrypsin crystal 
3.Terrilitin 
4.Trideceth 
5.Alteplase 
6.Deoxyribonuclease 
7.Ribonuclease 
8.Heparin 
64. Proteolytic enzymes for topical use 
1.Himopsin  
2.Collagenase  
3.Phosphatase 
65. Have a specific ability to inhibit the activity of trypsin, kallikrein, plasmin
and other proteases: 
1.Pantripin 
2.Aprotinin 
3.Ingitril 
4.Amiodaronum 
5.Counterbalance 
6.Gordox. 
66.Enzyme preparations: 
1.Fraxiparin 
2.Warfarin 
3.Streptokinase 
4.Penicillinase 
3.Prevention of repeated strokes and heart attacks.